RWM
WST icon

Revisor Wealth Management’s West Pharmaceutical WST Stock Holding History

Revisor Wealth Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$403K Sell
1,122
-152
-12% -$46.5K 0.1% 230
2026
Q1 		$318K Buy
1,274
+205
+19% +$51K 0.09% 242
2025
Q4 		$265K Sell
1,069
-98
-8% -$26.8K 0.07% 259
2025
Q3 		$306K Sell
1,167
-380
-25% -$92.4K 0.11% 207
2025
Q2 		$354K Buy
1,547
+144
+10% +$30.8K 0.13% 193
2025
Q1 		$314K Buy
1,403
+768
+121% +$212K 0.14% 163
2024
Q4 		$208K Sell
635
-401
-39% -$126K 0.19% 116
2024
Q3 		$311K Buy
1,036
+69
+7% +$21.1K 0.19% 121
2024
Q2 		$319K Sell
967
-542
-36% -$192K 0.22% 107
2024
Q1 		$564K Buy
1,509
+750
+99% +$277K 0.26% 104
2023
Q4 		$267K Sell
759
-287
-27% -$102K 0.31% 91
2023
Q3 		$392K Buy
1,046
+289
+38% +$112K 0.33% 69
2023
Q2 		$290K Sell
757
-168
-18% -$60K 0.26% 109
2023
Q1 		$320K Buy
+925
New +$270K 0.29% 85

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Revisor Wealth Management's WST Position: Q2 2026 in Review

Revisor Wealth Management reduced its West Pharmaceutical (WST) stake by 12% in Q2 2026, selling an estimated $46.5K and leaving 1,122 shares worth $403K. The position accounts for 0.1% of the portfolio, ranked #230.

Revisor Wealth Management first reported a position in WST in Q1 2023 and has held it in 14 quarters since. The position peaked at $564K in Q1 2024. 831 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Revisor Wealth Management held 1,122 shares of West Pharmaceutical worth $403K as of Q2 2026.
  • Revisor Wealth Management sold 152 West Pharmaceutical shares in Q2 2026, an estimated $46.5K.
  • West Pharmaceutical made up 0.1% of Revisor Wealth Management's portfolio in Q2 2026, its #230 holding.
  • Revisor Wealth Management first reported a position in West Pharmaceutical in Q1 2023 and has held it in 14 quarters since.
  • Revisor Wealth Management's West Pharmaceutical position peaked at $564K in Q1 2024.
  • 831 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Revisor Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.